Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cogent Biosciences (COGT) Short-term Investments (2017 - 2026)

Cogent Biosciences' Short-term Investments history spans 8 years, with the latest figure at $625.2 million for Q1 2026.

  • Quarterly Short-term Investments rose 422.46% to $625.2 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $625.2 million through Mar 2026, up 422.46% year-over-year, with the annual reading at $588.8 million for FY2025, 211.65% up from the prior year.
  • Short-term Investments came in at $625.2 million for Q1 2026, up from $588.8 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $625.2 million in Q1 2026 to a low of $1.3 million in Q2 2022.
  • The 5-year median for Short-term Investments is $190.6 million (2023), against an average of $204.7 million.
  • Year-over-year, Short-term Investments soared 17425.02% in 2024 and then crashed 59.91% in 2025.
  • Cogent Biosciences' Short-term Investments stood at $119.4 million in 2022, then soared by 77.97% to $212.5 million in 2023, then dropped by 11.09% to $188.9 million in 2024, then skyrocketed by 211.65% to $588.8 million in 2025, then grew by 6.19% to $625.2 million in 2026.
  • Per Business Quant, the three most recent readings for COGT's Short-term Investments are $625.2 million (Q1 2026), $588.8 million (Q4 2025), and $265.6 million (Q3 2025).